Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
Graham H JacksonCharlotte PawlynDavid A CairnsRuth M de TuteAnna HockadayCorinne CollettJohn R JonesBhuvan KishoreMamta GargCathy D WilliamsKamaraj KarunanithiJindriska LindsayAlberto RocciJohn A SnowdenMatthew W JennerGordon CookNigel H RussellMark T DraysonWalter Martin GregoryMartin F KaiserRoger G OwenFaith E DaviesGareth J Morgannull nullPublished in: PLoS medicine (2021)
ClinicalTrials.gov ISRCTN49407852.